Last reviewed · How we verify
amoxicillin, clarithromycin, metronidazole, rabeprazole
At a glance
| Generic name | amoxicillin, clarithromycin, metronidazole, rabeprazole |
|---|---|
| Also known as | AOC group: treated with amoxicillin, rabeprazole, clarithromycin for 7 days, AOM group: treated with amoxicillin, rabeprazole, metronidazole for 7 days, Sequential group: treated with amoxicillin, rabeprazole for 5 day, followed by clarithromycin, metronidazole, rabeprazole for 5 days, concomitant group: treated with amoxicillin, clarithromycin, metronidazole, rabeprazole for 7 days |
| Sponsor | The Catholic University of Korea |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection (PHASE4)
- Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies (PHASE3)
- The Observation on the Efficacy of Dual Therapy Based on Vonoprazan in Eradicating Helicobacter Pylori (NA)
- A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication (PHASE4)
- Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment (NA)
- 14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy (PHASE4)
- Helicobacter Pylori Eradication and Follow-up (PHASE4)
- Efficacies of Antimicrobial Susceptibility-Guided Versus Empirical Therapy for Rescue Treatment of Helicobacter Pylori Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: